CCORF Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $37
Piper Sandler Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Buy Rating Affirmed for Verona Pharma: Breakthrough COPD Treatment and Strategic Market Positioning
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN), Verona Pharma (VRNA) and Aveanna Healthcare Holdings (AVAH)
Optimistic Buy Rating for Verona Pharma Amidst Strong Ohtuvayre Launch and Expanding Clinical Trials
Verona Pharma Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)
Verona Pharma Analyst Ratings
Verona Pharma Analyst Ratings
Verona Pharma Analyst Ratings
Verona Pharma Analyst Ratings
Strategic Financing Secures Verona Pharma's Future Beyond 2026, Ensuring Buy Rating
Verona Pharma Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Verona Pharma (VRNA)
Verona Pharma Analyst Ratings
Buy Rating Affirmed on Verona Pharma Ahead of Ensifentrine's Expected FDA Approval and Strong Financial Standing
Verona Pharma Analyst Ratings
Truist Financial Sticks to Their Buy Rating for Verona Pharma (VRNA)
Buy Rating Affirmed: Verona Pharma's Promising Future With Ensifentrine and Expanding R&D Pipeline
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Verona Pharma (VRNA) and Molina Healthcare (MOH)